浙江医药：拟筹划控股子公司分拆赴港上市

Core Viewpoint - Zhejiang Medicine (600216) plans to spin off its subsidiary Zhejiang Xima Bio-Pharmaceutical Co., Ltd. for a listing on the Hong Kong Stock Exchange, with the board having approved the preparatory work [1] Group 1: Spin-off Details - The spin-off is currently in the preliminary planning stage, and specific plans have not yet been formed, indicating uncertainty [1] - The spin-off will not result in Zhejiang Medicine losing control over Xima Bio, nor will it adversely affect the operational development of other business segments or the overall profitability of the company [1] Group 2: Impact on Company Structure - The spin-off will not harm the independent listing status of Zhejiang Medicine [1]